Study Details

Back to Search Results

A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants with Duchenne Muscular Dystrophy (DMD)

Terminated/Withdrawn
The study has stopped early and will not start again. Participants were not enrolled (for withdrawn studies), however if participants were enrolled, they are no longer being examined or treated.

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT04184882

Astellas Study ID

The unique identification code given by the study sponsor.

0367-CL-0102

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Duchenne Muscular Dystrophy (DMD)

Phase

These clinical trials are usually the first time an experimental treatment is studied in a small group of people.

Phase 1

Age

8 Years - 16 Years

Sex

Male

Product

ASP0367

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Feb 2021 - Sep 2022

Masking

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Enrollment number

8

A Randomized, Double Blind, Placebo-Controlled Phase 1b Study With Open-Label Extension to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Patients with Duchenne Muscular Dystrophy (DMD)

Study summary

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants with Duchenne Muscular Dystrophy (DMD)? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Children's Hospital of The King's Daughters

Norfolk, United States, 23507

Children's Hospital of Richmond at VCU

Richmond, United States, 23219

University of California Davis Health

Sacramento, United States, 95817

University of Kansas Medical Center

Kansas city, United States, 66160

UMass Memorial Medical Center

Worcester, United States, 01655

University of Minnesota

Minneapolis, United States, 55455

Children's Hospital Los Angeles

Los Angeles, United States, 90027

Kennedy Krieger Institute

Baltimore, United States, 21201

Children's Hospital of Philadelphia

Philadelphia, United States, 19104

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo